Swiss reg­u­la­tors in­ves­ti­gate No­var­tis over 'un­law­ful abuse' of der­ma­tol­ogy patent

No­var­tis is be­ing in­ves­ti­gat­ed by an an­titrust watch­dog for as­sert­ing a patent, al­though the com­pa­ny says it stands by its move.

Reg­u­la­tors at the Swiss Com­pe­ti­tion Com­mis­sion paid a vis­it to No­var­tis’ head­quar­ters in Basel, the Swiss phar­ma gi­ant dis­closed in a terse state­ment.

Like many big play­ers with lu­cra­tive port­fo­lios to de­fend, No­var­tis has been no stranger to patent dis­putes — and it’s been on all sides of those spats, whether it’s try­ing to block gener­ics from en­ter­ing the mar­ket, be­ing sued for in­fringe­ment or get­ting in trou­ble for al­leged pay-for-de­lay schemes.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.